University of Kentucky College of Pharmacy, Lexington.
University of Kentucky College of Pharmacy, Lexington.
Am J Med. 2020 Jun;133(6):664-667. doi: 10.1016/j.amjmed.2020.01.031. Epub 2020 Mar 5.
Migraine is the third-most prevalent disease in the world and affects approximately 39 million individuals in the United States alone. Migraine occurs in nearly 1 in 7 individuals between 15 and 49 years of age and is 3 times more frequent in women than in men. The Food and Drug Administration (FDA) recently approved 3 new humanized monoclonal antibodies that target calcitonin gene-related peptide (CGRP): erenumab, fremanezumab, and galcanezumab. The agents either bind to the CGRP receptor (erenumab) or bind to the CGRP ligand (fremanezumab and galcanezumab) and block its binding to the receptor. All 3 products are indicated for preventative treatment of episodic or chronic migraine in adults. The available studies to date document that these agents reduce migraine attacks. The CGRP monoclonal antibodies offer patients new options once they have exhausted other treatments.
偏头痛是世界上第三大常见疾病，仅在美国就影响约 3900 万人。偏头痛在 15 至 49 岁人群中的发病率接近每 7 人中就有 1 人，且女性发病率是男性的 3 倍。美国食品和药物管理局（FDA）最近批准了 3 种针对降钙素基因相关肽（CGRP）的新型人源化单克隆抗体：erenumab、fremanezumab 和 galcanezumab。这些药物要么与 CGRP 受体结合（erenumab），要么与 CGRP 配体结合（fremanezumab 和 galcanezumab）并阻断其与受体的结合。所有这 3 种产品均被批准用于预防成人发作性或慢性偏头痛。迄今为止的研究表明，这些药物可减少偏头痛发作次数。当患者已用尽其他治疗方法时，CGRP 单克隆抗体为他们提供了新的选择。
